NCT01882387View on ClinicalTrials.gov

Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Hematologic Malignancies
Interventions
DRUG

TXA127

Injection, 300mcg/kg/day for 28 days

Trial Locations (2)

30322

Winship Cancer Institute, Emory University, Atlanta

63110

Siteman Cancer Center, St Louis

Sponsors
All Listed Sponsors
lead

Tarix Pharmaceuticals

INDUSTRY